Atrial fibrillation and mortality: The impact of antithrombotic therapy

European Heart Journal

Volumn 31, Issue 17, 2010, Pages 2075-2076

  Lane, Deirdre A ^a   Lip, Gregory Y H ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIVITAMIN K; CLOPIDOGREL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; WARFARIN;

BLEEDING; BLOOD PRESSURE; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CLINICAL TRIAL; EDITORIAL; HEART ATRIUM FIBRILLATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; RANKIN SCALE; STROKE; THROMBOEMBOLISM;

ATRIAL FIBRILLATION; FIBRINOLYTIC AGENTS; HEMORRHAGE; HUMANS;

EID: 77956405690     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehp486     Document Type: Editorial

References (7)

1. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007;46: 857-867.
2. The ACTIVE Writing Group on behalf of the ACTIVE Investigators. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for the prevention of Vascular Events (ACTIVE-W): a randomised controlled trial. Lancet 2006;367:1903-1912.
3. De Caterina R, Connolly SJ, Pogue J, Chrolavicius S, Budaj A, Morais J, Renda G, Yusuf S, on behalf of the ACTIVE Investigators. Mortality predictors and effects of antithrombotic therapies in atrial fibrillation: insights from ACTIVE-W. Eur Heart J 2010;31:2133-2140. First published on 4 August 2010. doi:10.1093/ eurheartj/ehq250.
4. van Walraven C, Hart RG, Singer DE, Laupacis A, Connolly S, Petersen P, Koudstaal PJ, Chang Y, Hellemons B. Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis. JAMA 2002;288:2441-2448.
5. Olsson SB; Executive Steering Committee of the SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet 2003;362:1691-1698.
6. Albers GW, Diener HC, Frison L, Grind M, Nevinson M, Partridge S, Halperin JL, Horrow J, Olsson SB, Petersen P, Vahanian A; SPORTIF Executive Steering Committee for the SPORTIF V Investigators. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA 2005;293:690-698.
7. Devereaux P, Anderson D, Gardner M, Putnam W, Flowerdew G, Brownell B, Nagpal S, Cox JL. Differences between perspectives of physicians and patients on anticoagulation in patients with atrial fibrillation: observational study. BMJ 2001;323:1218-1222.